Ocular Therapeutix (NASDAQ:OCUL) Upgraded by StockNews.com to “Hold”

StockNews.com upgraded shares of Ocular Therapeutix (NASDAQ:OCULFree Report) from a sell rating to a hold rating in a report issued on Tuesday.

Ocular Therapeutix Price Performance

NASDAQ OCUL opened at $5.68 on Tuesday. The company has a current ratio of 4.03, a quick ratio of 3.96 and a debt-to-equity ratio of 9.41. The company has a fifty day simple moving average of $4.33 and a 200 day simple moving average of $3.62. The company has a market cap of $451.11 million, a P/E ratio of -4.98 and a beta of 1.09. Ocular Therapeutix has a 1 year low of $2.00 and a 1 year high of $7.96.

Ocular Therapeutix (NASDAQ:OCULGet Free Report) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.24). The company had revenue of $15.08 million during the quarter, compared to the consensus estimate of $15.41 million. Ocular Therapeutix had a negative net margin of 116.18% and a negative return on equity of 589.24%. On average, sell-side analysts predict that Ocular Therapeutix will post -1.14 EPS for the current year.

Insider Transactions at Ocular Therapeutix

In related news, insider Rabia Gurses Ozden sold 7,764 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $4.95, for a total transaction of $38,431.80. Following the completion of the sale, the insider now owns 92,767 shares in the company, valued at approximately $459,196.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Antony C. Mattessich sold 18,338 shares of Ocular Therapeutix stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $4.95, for a total transaction of $90,773.10. Following the transaction, the chief executive officer now owns 427,943 shares of the company’s stock, valued at approximately $2,118,317.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rabia Gurses Ozden sold 7,764 shares of Ocular Therapeutix stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total transaction of $38,431.80. Following the transaction, the insider now directly owns 92,767 shares in the company, valued at approximately $459,196.65. The disclosure for this sale can be found here. In the last three months, insiders sold 39,366 shares of company stock valued at $194,862. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of OCUL. FMR LLC increased its holdings in Ocular Therapeutix by 84.4% during the first quarter. FMR LLC now owns 4,751 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 2,175 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Ocular Therapeutix by 350.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,192 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 7,152 shares during the period. Steward Partners Investment Advisory LLC boosted its position in shares of Ocular Therapeutix by 61.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 9,225 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 3,500 shares during the period. Victory Capital Management Inc. bought a new stake in shares of Ocular Therapeutix in the fourth quarter valued at about $45,000. Finally, Captrust Financial Advisors boosted its position in shares of Ocular Therapeutix by 2,000.0% in the second quarter. Captrust Financial Advisors now owns 10,500 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 10,000 shares during the period. Institutional investors own 54.42% of the company’s stock.

Ocular Therapeutix Company Profile

(Get Free Report)

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Further Reading

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.